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INTRODUCTION 
              The natural history of Benign Prostatic Hyperplasia(BPH) is 
variable. One of the most significant complications that a patient with 
Benign Prostatic Hyperplasia can experience is Acute urinary retention 
(AUR).Benign Prostatic Hyperplasia is a progressive disease. This 
concept is being slowly accepted. Acute Urinary Retention  is one of the  
long-term outcomes of benign prostatic hyperplasia. The exact incidence 
rates of acute urinary retention was uncertain till the recent past. 
However with the availability of population-based studies of 
community-dwelling men as well as those from patients diagnosed with 
BPH, better estimates of the incidence of AUR are currently available. 
The incidence rate per 1000 patient-years is less variable in the 
community than previously thought. This is the data inferred from 
descriptive and analytical studies. The estimated incidence rate is 5–25 
per 1000 person-years. It is approximately 0.5%–2.5% per year. Risk is 
cumulative . It increases with an increase in age. The cumulative risk of 
AUR in a fifty year old male , with mild symptoms of BPH, if he lives 
to be 80 is about 20%. The risk of AUR for a  sixty year old man who 
lives another twenty years is about 23%, and  that for seventy year old 
man who lives another 10 years, is about 30%.       
The impact that acute urinary retention can have on the quality of 
life is comparable to that of an of attack of renal colic.1  Even a single 
episode of urinary retention is  significant  for a patient with BPH. It  is 
characterized by the inability to void, increasing pain, and need for 
catheterization .Follow-up visits to the doctor is required with an 
attempt of trial voiding. If trial voiding fails, the patient may require 
surgery. The entire process is painful and time-consuming. The risk of 
recurrent retention  was  56%–64% within  1 week of the first episode as 
per the previously available data .2–4 
          The risk of acute urinary retention is higher in a patient with BPH 
when compared to the general population. Several strong risk factors  
for AUR have been identified by analytical studies. The most important  
risk factor is serum prostate-specific antigen (PSA).  The other risk 
factors are prostate volume, maximum flow rate, and symptom severity. 
These should be kept in mind when counselling patients with benign 
prostatic hyperplasia who are planned for medical management.       
There has been a remarkable change in the approach and 
management of patients with acute urinary retention. Several  factors hat 
can result in AUR or associated with AUR have been identified. AUR 
may be classified as that related to BPH or not related to BPH.  
It can be either spontaneous or precipitated. The management  involves 
urgent bladder decompression. This can be achieved by either urethral 
catheterization or suprapubic catheterization. All patients should 
undergo an attempt of trial voiding without catheter(TWOC). However a 
significant number of patients may not void. These patients require 
surgery usually within the first year of follow-up. 
    One of the  prophylactic measures attempted to prevent AUR in 
men with moderate to severe  LUTS and large sized prostate,  is the use 
of 5 alpha reductase inhibitors. Alpha blockers have also been used in 
symptomatic BPH patients to prevent AUR.  Its use can aid in voiding 
following catheter removal. The time of surgery after AUR can be 
delayed with the use of alpha blockers and in patients who is responding 
well, surgery can even be avoided. Anticholinergic drugs   can be used 
in combination  with alpha blockers in patient with BPH. This 
combination does not increase the risk of AUR. However conclusive 
evidence to prove  reduction of risk of AUR with  the use of finasteride 
and  α-blockers is still lacking. 
In the past, an episode of AUR was an absolute indication for 
surgery. Between twenty five to thirty percent  of men who underwent 
transurethral resection of the prostate (TURP) in the past had AUR as 
their main indication for surgery.5 At present only those patients who  
fails trial without catheter  undergo surgery.                         
TURP is the treatment of choice if a patient fails trial without 
catheter. It is the  “gold standard”.  Other minimally invasive procedures 
can be considered in poor-risk patients. The safety and efficacy of these 
procedures, however, is yet to be determined. 
    In contrast to patients presenting with symptoms only ,TURP has 
been found to be associated with increased morbidity and mortality in 
men with AUR . Delayed TURP is associated with lower morbidity and 
mortality than urgent intervention  in a patient who had an episode of 
AUR. Hence , it is justifiable to attempt primary prevention of AUR 
especially in those patients with increased risk such as older patients, 
patients with severe symptoms, larger sized  glands, and increased PSA 
levels. 
 
 
 
 
 
 
 
AIM OF THE STUDY 
     To accurately determine factors that predict acute urinary 
retention in patients with benign prostatic hyperplasia by comparing 
patients presenting with acute urinary retention to patients without 
retention. 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE  
Epidemiology of AUR in BPH 
    Several population-based, observational and placebo-controlled 
studies of AUR in BPH  are available. The results of these studies can 
be analyzed descriptively as well as epidemiologically. 
Descriptive Epidemiology 
The occurrence of  AUR was in the range of 4-15 to  one thirty 
per thousand person-years  as per previous estimates.  This was 
calculated by Jacobsen and colleagues6 based on studies by Birkhoff  et 
al,7 Ball et al,8 and Craigen et al,9. These studies gave a  ten year 
cumulative incidence rate of   four to seventy three percent. In a cross 
sectional study of Spanish men published in 2002, the self-reported rate 
of AUR was five percent.10 
Recent data  of AUR in BPH from  controlled studies in better-
defined populations are available. In the Veterans Association 
Cooperative study,  AUR occurred  in one man after TURP . It was 
noted in eight of 276 patients in the watchful waiting arm during a three 
year follow up period. The  incidence rate of AUR in this study was 9.6 
per thousand person-years.11 
      Five hundred men with BPH were studied by Barry and 
colleagues. These men  chose to undergo conservative treatment inspite 
of  being candidates for surgery  as per established criteria.12 In 1574 
person-years, during a four year follow up, forty episodes of AUR were 
observed. The incidence rate of  AUR was twenty five  per thousand 
person-years, in this study. 
    The Physician's Health Study observed that in 15,851 person-
years of follow-up, eighty two men developed acute urinary retention. 
The   incidence rate for AUR in this study was 4.5 per thousand person-
years .13 
      2115 men  between the ages of  forty and seventy nine were 
followed in the Olmsted County Study.During 8344 person-years of 
follow-up , fifty seven had their first episode of AUR. The incidence of 
AUR as per this study was 6.8 per thousand person-years .6 
  
 
The Proscar Long-Term Efficacy and Safety Study (PLESS)14 
followed 1376  men for four years. These men with enlarged prostates 
and moderate symptoms  were treated by placebo. AUR was noted in 
ninety nine of these men. The incidence of AUR as per this study was 
eighteen per thousand person-years. 
     Ameta-analysis of  threestudies with a similar number of enrolled 
patients ( 2109 patients) was carried out by Andersen and colleagues  . 
These studies involved a two year follow up of patients with BPH 
treated with placebo. Of the population  studies , fifty sevenhad AUR. In 
this meta analysis, the  incidence rate was fourteen  per thousand 
person-years .15 
Fig 1 –  Olmsted County Study done by Jacobsen et al6 –showing Incidence 
rates of acute urinary retention as per age and severity of symptoms 
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Birkhoff et 
al7 
Watchful 
waiting study 
10 26 3 39% 13% 130 
Ball et al8 Watchful 
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Mcconnell 
et al14 
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Jacobsen et 
al6 
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57 2115 4   6.8 
 
Analytical Epidemiology 
The risk factors for Acute Urinary Retention can be determined 
with the help of these studies.  
The Physician's Health Study showed that the rate of AUR 
increased with increasing age of the patient and baseline symptom 
Table 1 showing various studies with incidence rates of AUR 
severity 13. Theincidence  of AUR was observed to increase from 0.4 per 
thousand person-years in patients in the 45–49 year age range  to 7.9 per 
thousand person-years in patients in the 70–83 years age range.These 
patients had mild LUTS at the time of presentation.The highest risk of  
AUR was in those patients  a symptom score of eight or more.The age-
adjusted incidence in this group was 13.7 per thousand person-years.  
The risk of AUR was individually predicted by all the seven lower 
urinary tract symptoms (LUTS) that comprise the American Urological 
Association symptom index .The symptoms with most independent 
prediction of risk for AUR were the feeling of incomplete bladder 
emptying, having a weak urinary stream and the desire to void again 
within two hours of the last act. 
      The association with age, severity of symptoms , prostate volume 
and maximum flow rate was analysed in the Olmsted County Study6. 
The incidence rates per thousand person-years was noted to increase 
from 2.6 in the fourth decade  to 9.3 in the seventh decade for men with 
mild symptoms. It was observed to increase from 3.0 to 34.7, in those 
patients with moderate or severe symptoms. The relative risk for AUR 
increased for older men and in those with moderate to severe symptoms 
(3.2 times). The risk was also noted to be higher (3.9 times) in those 
with a flow rate below twelve  mL/sec . In those with a prostate volume 
of more than thirty mL as pertransrectal ultrasound, the risk was three 
times higher. The  baseline risk was 1.0 x for the corresponding groups.
 
 
A questionnaire-based study  from Germany evaluated  5404 men 
between the ages of fifty to eighty years. 1.9% incidence of AUR  was 
noted in the  first year of follow up.16 There was  good correlation of 
incidence with age and symptom severity.The incidence rate was 0.8%  
for men between the ages of fifty to fifty nine years. It wasone percent 
for those in the 60–69 years age range .For patients above 70 years, the 
incidence was 2.5%. The incidence rate of AUR for those with mild 
symptoms was about 0.7% and with moderate symptoms it was about 
Fig 2  –  Olmsted County Study ; Jacobsen et al 6: relative risks  of AUR as per 
age and severity of symptoms,prostate volume and flow rate. 
2.4% , where as in patients with severe symptoms it was about thirteen 
percent respectively. 
An  observational study of  three hundred and thirty one  men 
with BPH was carried out. Of those studied , the initial presentation was 
that of AUR in sixty four patients.17 No significant differences in terms 
of age, symptoms, and quality of life was observed in the two groups. 
However, in the patients with AUR, the  transition zone volume  and the 
total volume of the prostate were significantly higher. There was also a 
significant difference in the ratio of transition zone to total prostate 
volume (transition zone index ). This was  0.716 in the AUR group 
andabout 0.416 in the non-AUR group (P < .001). The amount of tissue 
resected  was also stastically significant in those with and without AUR 
(30.0 ± 29.8 SD vs 22.8 ± 26.7 SD cc; P < .01). This was demonstrated 
bySaboorian and colleagues who studied ninety men with AUR and 
eighty seven men without AUR.18 The levels of serum prostate-specific 
antigen prior to surgery was also found to be significantly different in 
the two groups (6.5 ± 5.5 SD vs 4.5 ± 4.6 SD; P < .001). 
     The risk of AUR was related to the prostate volume, symptom 
severity and serum PSA as shown in the PLESS study 14,20,21 . The same 
was also observed in three placebo driven two year studies 19.The 
incidence of AUR was found to increased from 5.6% in patients with 
mild symptoms and PSA of less than 1.4ng/ml to 7.7% in men with 
severe symptoms and similar PSA level. In patients in the PLESS study 
with serum PSA more than 1.4ng/ml the risk of AUR increased from 
7.8% to 10.2%  during the four years of follow up.20 In the  two year 
studies, the rate of AUR was noted to be  eight fold greaterif the serum 
PSA was more than 1.4 ng/mL (0.4% vs 3.9%). The risk was three times 
greater if the prostate volume was more than forty ml (1.6% vs 4.2%).19 
 
 
 
 
 
 
 
  
 
         Over hundred possible outcome predictorsof  AUR were analyzed  
alone or in combinations. This analysis revealed that levels of serum 
PSA alonewas  superiorwhen compared with  the combination of serum 
Fig 3 .Results of  PLESS. incidence calculated over 4 yearsand  stratified 
bytertiles of prostate volume serum prostate-specific antigen (PSA)  at 
baseline. 
PSA, symptom problem index, voiding within two hours of the last act , 
hesitancy and maximum urinary flow rate  in predicting an episode of 
acute urinary retention.22 
Mechanism of AUR may be due to  1. disruption of bladder 
innervation (spinal cord  injury, diabetes mellitus)   2.  any condition 
which leads to the overdistension of  bladder.(alcohol ingestion) 3.Also 
,urinary flow can be restricted by any event  which narrows the urethral 
lumen,thereby causing resistance to the flow (BPH,stricture urethra) .In 
BPH , the  main mechanism which precipitates AUR  has not been fully 
evaluated.However  followingfactors may  be considered  
Etiology of AUR. 
1.Prostatic inflammation     -     The first episode of AUR usually 
occurs following an event of prostatic inflammation . Kefi et al. 
reported,patients who presented with LUTS only had 29% of prostatic 
inflammation when compared to  men with AUR  who had only 
54.7%.23. MTOPS study,  concluded  that baseline prostate biopsies done 
among  1,197 patients  showing , acute inflammatory changes  in 544 
patients  and chronic inflammatory changes in 513 patients. Prostatic 
inflammation were predominantly  found to be associated with patients 
having increased PSA values and also large sized glands.Both increased 
size of prostate  and raised PSA levels  were considered as predicting 
factors for AUR in BPH. These patients also have rapid  progression of  
symptoms and are  more likely to undergo surgery when compared with 
those who had no inflammation.24The  cause for inflammation in BPH 
resected specimens  has not been clearly identified. The presence of  
large amount of CD4(+) T lymphocytes may suggest the possibility of 
autoimmune etiology.This was also confirmed by increased levels of 
inflammatory cytokines which are released by smooth muscle cells and 
T cells .These cytokines are interleukin 15 (IL-15) and interferon 
gamma (IFN-gamma).25 
2.Prostatic infarction26 -    Infarction of prostate  may cause AUR.  
This was confirmed by the study conducted by Spiro and 
colleaguesl.27They compared the prostatectomy specimens between 
patients with AUR and those with symptoms alone.Theyfound that  85% 
of prostates removed for AUR  showed infarction where as it was  only 
3% in patients with symptoms alone.Infection , trauma  following  
instrumentation,compromising intraglandularblood supply all can cause 
prostatic infarction .The exact mechanism by which  prostatic infarction 
causing  has not been determined. A proposed model for AUR due to 
prostatic infarction by Abeshouse et al28 may be the following 
  
Anjum and colleagues done similar study comparing the 
prostatectomy specimens of thirty  five men with AUR and thirty five 
men without urinary retention. They found that three percent of men 
with AUR showed infarction of prostate and it was only 1.9% men 
showed infarction without retention29. In contrast,study conducted by 
Jacobsen et al does not any infarction in six prostatectomy  specimens of 
men with AUR.30To know the exact role of prostatic infarction as a 
cause for AUR , conclusive studies are pending. 
3.Alteration in Stromal and Epithelial ratio  -A prospective 
controlled trial of clinico-pathological study compared the specimens 
Prostatic infarction 
 
Swelling  of prostate 
 
Rise in intraluminal prostatic urethral pressure  
 
Increased efferent activity of alphaadrenergic nerves 
 
Intraurethral pressure further get increased 
 
Development of AUR. 
FIG 4  - Prostatic infarction – etiology of AUR 
retrieved from patients with AUR and patients with refractory lower 
urinary tract symptoms only . Both the groups had equal number of 
patients of about 35 in each.This study showed that patients with acute 
urinary retention had increased epithelial component of about 71% 
,when compared with patients with symptoms only who had only about 
60% . The alteration in ratio of  epithelial and stromal growth may cause 
disruption in the blood supply of the gland ultimately resulting in 
infarction of prostate and finally causing acute urinary 
retention.Finasteride , 5 alpha reductase inhibitor has its action mainly 
on the epithelial component of the prostate gland. Its use found to 
decrease the incidence of acute urinary retention .This supports the fact 
that alteration in Stromal and Epithelial ratiowith increased epithelial 
component may cause AUR. 
4.Genitourinary instrumentation    - Acute urinary retention can 
be caused by any of the diagnostic procedures like  cystoscopy, 
ureteroscopy ,prostatic biopsy in the immediate post operative  period. 
This is usually due to irritation to genitourinary tissues and also 
sometimes by hematuria. The incidence of acute urinary retention has 
been decreased after the use of flexible cystoscopy. This may be due to 
the fact that flexible cystoscopy causing  less trauma to the genito 
urinary tissues  and also lesser irritation.Bigger  sizedtru-cut needles 
used in trans rectal biopsy of prostatemay cause acute urinary 
retention.This is usually due to the traumatic insult  to the prostatic 
tissues with hematoma and swelling causing urinary 
retention.Sometimes associated  hematuriawith clots can also cause 
urinary retention. Smaller sized needles used under TRUS guidance 
rarely produce acute urinary retention .31 AUR  following ureteroscopyis 
usually due to  bladder irritation. 
5.Postoperative AUR     -The presence or absence of BPH does 
not alter the occurrence of AUR in the post operative 
period.32Anesthesia, analgesia, pain , suppressed consciousness 
,intravenous fluids  all may cause postoperative AUR.  An intravenous 
infusion of more than 0.75 liter and advanced age are found to be the 
better predictors of AUR in post operative period. This was proposed by 
Hawa et al. 
6.Constipation  -   In the absence of scarce fecal impaction, 
neurological disease,or   bladder outlet obstruction ,constipation may 
also be considered as a cause for acute urinary retention. Alfuzosin in 
Acute Urinary Retention (ALFAUR) study conducted with , 363 BPH 
patients  presenting with AUR. Thorough  history of daily bowel habits 
was taken from all the patients. The study concluded that results of trial 
of voiding whether failed or successful ,does not depends on the 
constipation history.However  patient with constipation are at increased 
risk for recurrent episodes of urinary retention and may need surgical 
intervention for BPH. 
7.Stroke (CVA) - Impaired bladder emptyingis one of the 
neurological sequelae of stroke which can precipitate AUR. 
8.Alcohol ingestion  -Central nervous system suppression and 
also fluid overload ,both combined  together may cause acute urinary 
retention. 
The presence or absence of BPH does not alter the occurrence of 
AUR in stroke and also in alcohol ingestion. 
9.Drugs- Anti cholinergic drugs ,by detrusor relaxation and alpha 
agonists , by increasing bladder outlet resistance will cause  urinary 
retention. Drugs used for depression, allergies ,Parkinson's disease  
cause AUR by  anticholinergic actions. Drugs  used over-the-counter 
cold remedies have alpha-agonists as their common component also 
cause retention.  
As per  Athanasoupolos et al. inurodynamically proven bladder 
outlet obstructed patients,tolterodine can safely administered along  with  
alpha antagonist , without developing of urinary retention.33 Reynard et 
al. concluded that  anticholinergic drugscan be safely used in BPH 
patients .they also stated that the risk of developing urinary retention is 
very meagre and only effect that    patients had was minimal raise in 
post-void residual urine volume.34The ideal situations  where 
anticholinergic drugs is of use in BPH ,are that patients with more 
irritative LUTS and low post-void residual urine volume.  
Non-steroidal anti-inflammatory drugs (NSAIDS) -Contractionsof 
detrusor muscle is also caused by prostaglandin (PGE2).NSAIDs  
inhibit prostaglandin synthesis (PGE2),and cause urinary retention.35 
According to a  population-based and case control study done in 
men >45 years in Netherlands  ,current users of NSAIDs had a 2.02 
times increased risk of developing urinary retentionwhen compared to 
nonusers. The highest risk is for patients who have started taking 
NSAIDs recently. The dose may be eitherequal  or higher than the 
recommended daily dose. However there was no association noted 
between past use of NSAIDs and  AUR.  
10.Urinary tract infection (UTI)   - Infection causes acute 
inflammation and oedema of the bladder mucosa. mucosal ‘thickening’ 
can lead to urinary retention. This may resolve once the infection is 
treated appropriately with antibiotics. 
Urinary tract infection  may  precipitate  or complicate  
AUR.Urinary tract infection may  also arise  due to  poor bladder 
emptying secondary to BPH . Voiding function should be  assessed 
thoroughly when a man presents with  UTI and AUR . 
11. Bladder overdistension,36 a.regional anesthesia, 
b.prolongedlabourc.long duration surgery.      In all of the above 
conditions,urinary retention is usually undiagnosed and also 
incompletely treated.  This will result in prolonged overdistended 
bladder in a short duration. This ultimately cause temporary neurogenic 
detrusor decompensation (myogenic bladder damage) . Bladder 
sensation  is also affected,either decreased or absent . In these patients 
retention  symptoms are obscured and treatment is also not started 
promptly . 
12.Excessive fluid intake   -   An enlarged prostate can lead to 
bladder outflow obstruction by occluding  the urethral lumen. Acute 
painful urinary retention can occur in men with enlarged prostate when 
they drink  large amount of fluids or refrains from emptying his bladder 
for a longer period than usual. This may be due to stretching of the 
detrusor muscle and combination of poor detrusor muscle function and 
outflow obstruction lead to AUR. 
13.Bed-rest37 .   - Decreased mobility and increased bed rest – may 
be considered one of the reasons for post operative urinary retention. 
14 .Sexual activity, 
15. Debility,  
'Spontaneous' vs 'Precipitated' AUR    - AUR  can be classified 
in to spontaneous and precipitated.Although this classification is helpful 
in assessing the prognosis of patients clinically,this is not followed 
routinely.  
AUR Precipitated  type-  the inability to void which is usually 
associated with  a triggering event,  
1. treatment of drugs with anticholinergic or sympathomimetic 
actions, 
2. pelvic surgeries, non prostate related surgeries, 
3. following anesthesia, or  
AUR spontaneous type – urinary retention occurring with out any 
triggering events .21,38 
The prognosis and treatment results of AUR patients can be easily 
determined by this classification. When comparing both the types ,15% 
of men in spontaneous AUR type, experienced second event of 
retention, whereas it was only 9% in precipitated type. Also 75% of men 
underwent surgery in spontaneous type, whereas it was only 26% in 
precipitated type.21 
        In all cases of AUR ,initial evaluation involves the exclusion of 
BPH as a cause for retention. Although in majority of patients , BPH is 
the cause,patient should be offered  an alpha blocker followed by trial 
voiding without catheter     after a period of three to five days. 
In both types of urinary retention ,whether BPH is considered as a 
cause  or associated factor ,initial treatment option is the same for both 
types (offered  an alpha blocker followed by trial voiding without 
catheter).However in precipitated type, the factor which had precipitated 
found to alter the long term result, hence it should also be properly given 
importance in long term management.39 
AUR – Predicting factors 
In BPH, the predicting factors for AUR can be categorized in to 
baseline and dynamic variable factors.  
Base line variable factors are    -    
 1.advanced age  
2.lower urinary tract symptom severity 
3.decreased  peak flow rate 
4.raised post void residual volume of urine(PVR) 
5.enlarged prostate6. Increased PSA level  
7.previously conservatively treated AUR  
Dynamic variable factors are 
1. > 4 points deterioration of IPSS, 
2.during treatment , worrisome score >3 points  
3.raising post void residual volume of urine(PVR) 
4.refractory to alpha blockers     
For patients who are on conservative treatment ( watchful waiting  
or taking drugs)the above dynamic variable factors must be closely 
evaluated. This can help to predict which group of patient will go in for 
retention and those who are at risk advised to undergo surgical 
intervention. 40 
  
MATERIALS AND METHODS 
STUDY GROUP:   All men presenting with LUTS, with and 
without retention,  clinically and radiologically diagnosed to have  BPH 
, attending urology OPD and inpatients at GKMCH  and GRH beween 
March 2012 – Feb 2013 were included in the study. 
STUDY DESIGN:     Prospective observational analytical study. 
INCLUSION CRITERIA:  
1. Patients in the age group between 49-85 years. 
2. Clinically and radiologically diagnosed BPH patients. 
3. Patients presenting with  spontaneous  AUR . 
EXCLUSION CRITERIA:  
1. Patients with  post spinal injury, spinal degenerative and disc 
prolapse diseases. 
2. Patients presenting with  precipitated  AUR . 
3. Patients with stone disease 
4. Patients with carcinoma prostate  
This is a prospective observational analytical study  conducted at 
GKMCH/GRH from March 2012 to Feb 2013. The study was approved 
by instituitional ethical committee and all men gave written informed 
consent. 63 patients were enrolled in the study. Among them,32  patients 
presented with AUR and  31 patients presented with LUTS only. The 
diagnosis of BPH in all patients were confirmed  clinically and 
radiologically. All patients age, comorbid illnessess, previous  history of 
AUR were recorded. 
      Symptoms were assessed with IPSS grading (0 – 35). 
mild  : 0 – 7,moderate : 8 -19 , severe : 20 -35. All patients had moderate 
to severe symptoms. The patients with AUR were asked to record their 
symptoms for one month before urinary retention. Digital rectal 
examination(DRE) was done to grade the prostate size clinically. 
Depending upon the length of the prostate that encroaches in to the 
rectal lumen(vertical prominence)41, prostatic enlargement graded as 
follows, 
Tab 2- size grading by DRE.   
SIZE DIGITAL  RECTAL EXAMINATION 
Normal  Encroaches 0 to 1 cm rectal lumen 
I 1 to 2 cm  
II 2 to 3 cm 
III 3 to  4 cm 
IV >4 cm 
On DRE, apart from grading of enlargement, consistency, 
symmetry of the prostate gland, presence or obliteration of 
median furrow and  lateral sulci were assessed. The presence of 
nodules were also recorded. 
      USG study was done transabdominally to estimate prostate size, 
bladder wall thickness (BWT )and intravesical protrusion of prostate 
(IPP). Prostate size was calculated  using prostate ellipsoid formula-  
π/6 × anteroposterior(AP) × transverse (T) × sagittal(S)diameter. 
Depending upon the size of enlarged prostate, ultrasound grading can be 
as follows,41 
Tab 3 - USG  - SIZE GRADING 
NORMAL <20 gm 
I 20 – 40 gm 
II 40 – 60 gm 
III 60 – 90 gm 
IV >90 gm 
 
Bladder wall thickness was measured by USG, keeping the probe 
suprapubically from the anterior wall of the bladder in a partially filled 
bladder with 150 ml . 
  
 
 The degree of intravesical protrusion of  prostate(IPP) can be 
graded by measuring from the tip of the protruding prostate 
perpendicularly to the circumference of the bladder at the base of the 
prostate gland 42.  
 
 Figure – 6 - Measurement of intravesical projection of prostate in  USG STUDY 
Figure 5  - Measurement of bladder wall thickness 
 Depending upon the length of  intravesical protrusion of prostate , 
gradings are as follows . 
Grade 1 <5mm 
Grade 2 5-10 mm 
Grade 3. > 10 mm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure – 7 - USG PICTURE -  No intravesical projection 
Figure – 8 - USG PICTURE – GR I (< 5mm)  intravesical projection 
Table 4- intravesical protrusion (IPP)grading 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 - USG PICTURE –GR III  (> 10 mm) intravesical projection 
Figure 9 - USG PICTURE - GR II ( 5 – 10 mm) intravesical projection 
Routine haemogram and blood biochemistry were performed. 
Urine analysis / urine culture and  sensitivity  was done by collecting 
mid stream samples in non –AUR group and samples were collected  
directly from urethral catheter in AUR group patients.  
      Sr. PSA assessed with immunoradiometric assay. Samples were 
taken in OP clinic or in the patients ward before insertion of  the 
catheter. If patient presents to our clinic with inserted catheter, latest 
PSA done at OP clinic were used for comparison .In suspicion of 
Carcinoma prostate – transrectal biopsy were performed. Patient with 
biopsy proved  Carcinoma prostate, were excluded from the study. 
The mean, Standard deviation, minimal, maximal values were 
calculated and the baseline parameters values in AUR/non AUR groups 
were analysed usingstudent unpaired t test. All discrete variables were 
analysed by Chi Square test. All data were analysed using SPSS 
computer program and p <0.05 was considered statically significant. 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
      We planned to compare the following factors between AUR/ 
nonAUR groups. 
1.Age ,2.comorbid illnesses,3.previous history of urinary 
retention,4.IPSS symptom severity and grading ,5. Prostate size grading 
as per digital rectal examination (DRE),6.size of prostate as per 
ultrasound study ,7.thickness of bladder wall(BWT)by ultrasound 
,8.intravesical protrusion (IPP) grading by ultrasound  ,9. serum PSA 
level and 10.presence of urinary tract infection. 
       In our study among the 63 patients,2 patients in AUR group (one 
having  treatment with antidepressants,   one with neurogenic bladder 
dysfunction) and one in non AUR group (who had biopsy confirmed 
carcinoma prostate) were excluded.   
Statiscal package for social sciences,version 12.0.2 (SPSS, inc 
,Chicago, USA)was used for statistical analysis.level  of significance 
was considered with the p value of  < 0.05. 
 
 
 
1.AGE DISTRIBUTION Tab  5 - Crosstab – Age distribution 
   AUR 
   0 –NO 1 - YES Total 
AGE GROUP 0 Count 1 1 2 
    
% of Total 1.7% 1.7% 3.3% 
1 Count 13 12 25 
    
% of Total 21.7% 20.0% 41.7% 
2 Count 7 10 17 
    
% of Total 11.7% 16.7% 28.3% 
3 Count 9 5 14 
    
% of Total 15.0% 8.3% 23.3% 
4 Count 0 2 2 
    
% of Total .0% 3.3% 3.3% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests – 3.712   p    0.446    NOT   SIGNIFICANT. 
 
Figure – 11 – Age distribution 
Most of the patients in both groups belong to 51 – 60 years age group . 
AGE GROUP:  
Tab 6 - T TEST-Group Statistics 
 
AUR N Mean 
Std. 
Deviation 
Std. Error 
Mean 
AGE 1 – yes 30 64.23 8.889 1.623 
0 – no 30 64.83 8.518 1.555 
  
0 - <50 YEARS 
1 – 51 TO 60 YEARS 
2 – 61 TO 70 YEARS 
3 – 71 TO 80 YEARS 
4 - > 80 YEARS 
NO 
    AUR 
YES 
Independent Samples Test 
  Levene's Test for 
Equality of 
Variances 
t-test for Equality  
of Means 
    
  
F Sig. t Df 
Sig.  
(2-tailed) 
AGE Equal variances 
assumed 
.105 .747 -.267 58 .790 
Equal variances 
not assumed 
  
-.267 57.895 .790 
 
T - 0.267   p 0.790 NOT SIGNIFICANT. 
 
      Both groups were matched for appropriate age. The mean age for 
AUR group  was 64.23 years and for non AUR group was 64.83. 
There was no statistical significance between the various age 
groups between AUR and non AUR group as shown by p 0.79. 
 
  
  
   AUR  
   0 – NO 1 – YES Total 
Comorbid 0 Count 14 12 26 
    
% of Total 23.3% 20.0% 43.3% 
1 Count 2 6 8 
    
% of Total 3.3% 10.0% 13.3% 
2 Count 6 2 8 
    
% of Total 10.0% 3.3% 13.3% 
3 Count 4 6 10 
    
% of Total 6.7% 10.0% 16.7% 
4 Count 1 0 1 
    
% of Total 1.7% .0% 1.7% 
5 Count 1 2 3 
    
% of Total 1.7% 3.3% 5.0% 
6 Count 1 1 2 
    
% of Total 1.7% 1.7% 3.3% 
7. Count 1 1 2 
    
% of Total 1.7% 1.7% 3.3% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
 
Chi-Square Tests – 5.887, p    0.553, NOT SIGNIFICANT. 
2.COMORBID ILLNESSES 
TABLE 7 – DISTRIBUTION OF COMORBID ILLNESSESS 
 Figure 12 – Distribution of comorbid illnessess 
 
Most of the patients in both groups have no associated comorbid 
illnesses.  
      There was no statistical significance in concern with presence of 
any of the comorbid illnesses diabetes mellitus, systemic hypertension, 
ischemic heart disease, COPD, pulmonary tuberculosis  between the 
AUR/nonAUR groups, as shown by p   0.553. 
 
  
AUR 
NO 
YES 
0 –  NO COMORBID 
ILLNESS 
1 – DM  + SHT 
2 -  SHT ALONE 
3 -  DM ALONE 
4 – DM + IHD 
5 – SHT + IHD 
6 – DM + SHT + IHD   
7  - COPD / PT 
YES 
6          7 
4. PREVIOUS  AUR  EPISODES 
TABLE 8 – Crosstab for  prior AUR 
   AUR  
   0 –NO 1 –YES Total 
PREVIOUS  
AUR  
EPISODES 
0-NO Count 28 20 48 
    
% of Total 46.7% 33.3% 80.0% 
1-
YES 
Count 2 10 12 
    
% of Total 3.3% 16.7% 20.0% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests -  6.667, p  0.010 STATISTICALLY SIGNIFICANT. 
 Figure 13 – Prior AUR association 
 
 Eventhough most of the patients in both groups had no previous 
AUR episodes,   
 There exists a statistical significance between AUR  and  non 
AUR groups with respect  to  past history of  urinary retention with a  
p 0.010. 
 
 
 
AUR 
NO 
YES 
0 – NO PREVIOUS  
AUR EPISODES. 
1 – PREVIOUS  AUR 
EPISODES 
PRESENT. 
YES 
5. IPSS-GRADE 
TABLE 9 – Crosstab for IPSS severity 
   AUR  
   0 -NO 1-YES Total 
IPSS-
GRADE 
2 Count 27 21 48 
    
% of Total 45.0% 35.0% 80.0% 
3 Count 3 9 12 
    
% of Total 5.0% 15.0% 20.0% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests – 3.75  ,p 0.053   NOT SIGNIFICANT. 
 Figure 14 – IPSS severity distribution 
 
Most of the patients  in both groups presented with moderate IPSS 
score(8 -19) 
T TEST     -  TABLE 10 -Group Statistics 
 
AUR N Mean 
Std. 
Deviation 
Std. Error 
Mean 
IPSS 1 – yes 30 20.60 5.709 1.042 
0 – no  30 15.30 3.064 .559 
 
 
AUR 
NO 
YES 
2 –  IPSS 
MODERATE 
SCORE(8 - 19) 
3 – IPSS 
SEVERE SCORE 
(20 -35) 
YES 
Independent Samples Test 
  Levene's Test 
for Equality of 
Variances 
t-test for Equality of 
Means 
    
  
F Sig. T df 
Sig.  
(2-tailed) 
IPSS Equal variances 
assumed 
12.845 .001 4.480 58 .000 
Equal variances not 
assumed   
4.480 44.429 .000 
T   4.48    .p 0.000    STATISTICALLY SIGNIFICANT . 
 
Mean IPSS score for AUR group was 20.6 and for non AUR 
group ,15.3 with a statistical significance , p   0.000. 
 
 
 
 
 
 
 
 
 
 
 6. Digital rectal examination(DRE) grading 
TABLE 11 – Crosstab for DRE grading 
   AUR  
   0 –NO 1- YES Total 
DRE 0 Count 2 0 2 
    
% of Total 3.3% .0% 3.3% 
1 Count 14 9 23 
    
% of Total 23.3% 15.0% 38.3% 
2 Count 12 18 30 
    
% of Total 20.0% 30.0% 50.0% 
3 Count 2 3 5 
    
% of Total 3.3% 5.0% 8.3% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests -  4.487   ,    p  0.213  NOT  SIGNIFICANT. 
 Figure 15 – DRE size grading distribution 
 
Most of the patients in AUR group found to have GR II  
enlargement(2 -3 cm), and in non AUR group had GR I (1-2 cm) 
enlargement. 
There was no statistical significance between the two groups in 
concern with DRE grading as shown by p  0.213. 
  
AUR 
NO 
YES 
0 – DRE NORMAL ( 0 -1 
CM ENCROACHMENT 
IN TO RECTAL LUMEN) 
1 – GR I 
ENLARGEMENT (1 – 2 
CM ) 
2 – GR II 
ENLARGEMENT (2 – 3 
CM) 
3 – GR III 
ENLARGEMENT (3 – 4 
CM) 
YES 
  
 
   AUR  
   0-NO 1 –YES Total 
SIZE-GRADE 0 Count 0 1 1 
    
% of Total .0% 1.7% 1.7% 
1 Count 17 8 25 
    
% of Total 28.3% 13.3% 41.7% 
2 Count 10 14 24 
    
% of Total 16.7% 23.3% 40.0% 
3 Count 2 4 6 
    
% of Total 3.3% 6.7% 10.0% 
4 Count 1 3 4 
    
% of Total 1.7% 5.0% 6.7% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests – 6.573, p 0.160   NOT SIGNIFICANT . 
6. SIZE-GRADE  -  USG STUDY 
TABLE 12 – Crosstab for distribution of various size of prostate 
 
 Figure – 16 – Prostatic size distribution by USG 
Most of the patients in AUR group found to have GR II  
enlargement (41 – 60gms), and in non AUR group had GR I 
enlargement (21 - 40 gms ) 
T TEST         -       TABLE 13 - Group Statistics 
 
AUR N Mean 
Std. 
Deviation 
Std. Error 
Mean 
USG 
SIZE 
1 – yes 30 50.97 21.744 3.970 
0 – no 30 35.43 16.032 2.927 
 
 
AUR 
NO 
YES 
0 –  < 20 GMS  
1 – 21 – 40 GMS  
2 – 41 – 60 GMS 
3 – 61 -90 GMS 
4 -  >90 GMS 
YES 
Independent Samples Test 
  Levene's Test  
for Equality of 
Variances 
t-test for Equality of 
Means 
    
  
F Sig. T df 
Sig.  
(2-tailed) 
SIZE Equal variances 
assumed 
1.812 .184 3.149 58 .003 
Equal variances 
not assumed   
3.149 53.337 .003 
 
T – 3.149     p  0.003  STATISTICALLY SIGNIFICANT.  
 
Mean volume of the prostate gland was about 50.97gms in AUR 
group and in the non AUR group it was 35.43 with a statistical 
significance, p  0.003 . 
 
 
 
 
 
 
 
 
7. BLADDER WALL THICKNESS-  GRADE - USG STUDY 
TABLE 14 – Crosstab for BWT grading 
   AUR  
   0 -NO 1 –YES Total 
BWT 
GRADE 
0-
<5mm 
Count 19 10 29 
    
% of Total 31.7% 16.7% 48.3% 
1-
>5mm 
Count 11 20 31 
    
% of Total 18.3% 33.3% 51.7% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests – 5.406    , p  0.020    STATISTICALLY SIGNIFICANT. 
 
Figure 17 – BWT grading distribution 
 
Most of the patients in AUR group had thickness of  more than 5 
mm, where as in the non AUR group it was less than 5mm with a 
statistical significance, p  0.020.    
T TEST       -    Table 15 - Group Statistics 
 
AUR N Mean 
Std. 
Deviation Std. Error Mean 
Bladder 
wall 
Thickness 
1 – yes 30 6.13 1.074 .196 
0 – no 30 5.50 1.042 .190 
 
  0 -  < 5MM 
THICKNESS 
  1 -  > 5MM 
THICKNESS  
AUR 
NO 
YES 
 T – 2.318    p  0.024    STATISTICALLY SIGNIFICANT . 
 
Mean bladder wall thickness in AUR group was 6.13 mm and in 
non AUR group it was 5.5mm with statistical significance , p 0.024. 
 
 
 
 
 
 
 
 
Independent Samples Test 
  Levene's Test 
for Equality of 
Variances 
t-test for Equality of 
Means 
    
  
F Sig. T df 
Sig.  
(2-tailed) 
BWT Equal variances 
assumed 
.155 .695 2.318 58 .024 
Equal variances not 
assumed 
  2.318 57.947 .024 
8. INTRAVESICAL PROSTATIC PROJECTION 
Table 16 – Crosstab for IPP grading 
   AUR  
   0–NO 1-YES Total 
IPP 0 Count 17 5 22 
    
% of Total 28.3% 8.3% 36.7% 
1 Count 7 10 17 
    
% of Total 11.7% 16.7% 28.3% 
2 Count 5 11 16 
    
% of Total 8.3% 18.3% 26.7% 
3 Count 1 4 5 
    
% of Total 1.7% 6.7% 8.3% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests–11.125  , p   0.011  STATISTICALLY SIGNIFICANT. 
 Figure 18-  IPP grading distribution 
 
Most of the patients in AUR group had GR II IPP (5 – 10 mm) 
where as, in the non AUR group it was GR 0 (no IPP) with a statistical 
significance, p 0.011. 
 
 
 
 
 
 
     AUR 
NO 
YES 
0 – NO 
INTRAVESICAL 
PROJECTION 
1 – GR I 
PROJECTION 
(< 5 MM)  
2 – GR II 
PROJECTION 
( 5 – 10  MM) 
3 – GR III 
PROJECTION 
(> 10 MM) 
YES 
9. SERUM PSA 
Table 17 – Crosstab for sr  PSA levels 
   AUR  
   0- NO 1-YES Total 
PSA  0 Count 18 13 31 
    
% of Total 30.0% 21.7% 51.7% 
1 Count 12 13 25 
    
% of Total 20.0% 21.7% 41.7% 
2 Count 0 4 4 
    
% of Total .0% 6.7% 6.7% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
Chi-Square Tests – 4.846,  p   0.089      NOT SIGNIFICANT. 
 Figure 19 –Distribution of  various PSA levels 
Most of the patients in non AUR group had PSA < 4 ng/ml   
where as , in the  AUR group there were equal number of patients with 
< 4ng/ml and  4 – 10 ng /ml. 
T- test 
Table 18 - Group Statistics 
 
AUR N Mean Std. Deviation 
Std. Error 
Mean 
PSA 1 –yes 30 6.016000 5.5069822 1.0054328 
0 – no 30 3.593333 1.8600952 .3396054 
  
AUR 
NO 
YES 
0     -      <4  ng/ml 
1    –    4 -10 ng/ml 
2    -     > 10   ng/ml 
YES 
Independent sample test 
 
 
 Levene's Test 
for Equality of 
Variances 
t-test for Equality of 
Means 
    
  
F Sig. T df 
Sig.  
(2-tailed) 
PSA Equal variances 
assumed 
8.139 .006 2.283 58 .026 
Equal variances 
not assumed   
2.283 35.532 .029 
 
T – 2.283    p  0.026   STATISTICALLY SIGNIFICANT. 
 
Mean PSA level in the AUR group was about 6.02ng/ml and in 
the non AUR group it was 3.59ng /ml  with a statistical significance ,  
p  0.026. 
 
 
 
 
 
 
 
 
10. URINE CULTURE - Table 19 – Crosstab for UTI association 
   AUR  
   0 –NO 1 – YES Total 
URINE CULTURE 0 Count 18 15 33 
    
% of Total 30.0% 25.0% 55.0% 
1 Count 5 8 13 
    
% of Total 8.3% 13.3% 21.7% 
2 Count 3 2 5 
    
% of Total 5.0% 3.3% 8.3% 
3 Count 1 0 1 
    
% of Total 1.7% .0% 1.7% 
4 Count 3 5 8 
    
% of Total 5.0% 8.3% 13.3% 
 Total Count 30 30 60 
    
% of Total 50.0% 50.0% 100.0% 
 
Chi-Square Tests -  2.665,    p 0.615    NOT SIGNIFICANT. 
 
 Figure 20 – Distribution of urine culture reports 
 
Most of the patients in both the groups showed no organisms 
grown  in urine culture . 
There was no statistical significance between the two groups in 
concern with urine culture positivity with a p  0.615.   
 
  
AUR 
NO 
YES 
0 – NO GROWTH 
1 -  E.COLI 
2 - PSUEDOMONAS 
3 – STAPH AUREUS 
4  - KLEBSILLA 
YES 
DISCUSSION  
In men older than 50 years, benign prostatic hyperplasia (BPH) is 
a common disease. The incidence of BPH in this age group is about 19-
30%  43.Deterioration of bladder  detrusor function, urinary tract 
infection, obstruction induced renal failure and also acute urinary 
retention (AUR) are all long-term consequences of the BPH44. 
 The impact that acute urinary retention can have on the quality of 
life is comparable to that of an of attack of renal colic.1  Even a single 
episode of urinary retention is  significant  for a patient with BPH.  It  is 
characterized by the inability to void , increasing pain, and need for 
catheterization .Follow-up visits to the doctor is required with an 
attempt of  trial voiding. If trial voiding fails , the patient may require 
surgery. The entire process is painful and time-consuming . The risk of 
recurrent retention  was  56%–64% within  1 week of the first episode as 
per the previously available data .2–4 
          The risk of acute urinary retention is higher in a patient with BPH 
when compared to the general population. Several strong risk factors  
for AUR have been identified by analytical studies. The most important  
risk factor is serum prostate-specific antigen (PSA).  The other risk 
factors are prostate volume, maximum flow rate, and symptom severity. 
These should be kept in mind when counseling patients with benign 
prostatic hyperplasia who are planned for medical management.       
There  has been a remarkable change in the approach and 
management of patients with AUR. Several factors that can result in 
AUR or associated with AUR have been identified. AUR may be 
classified as  that related to BPH or not related to BPH. It can be either 
spontaneous or precipitated. The management  involves  urgent bladder 
decompression . This can be achieved by either urethral catheterization 
or suprapubic catheterization.  All patients should undergo an attempt of 
trial without catheter. However a significant number of patients may  not 
void. These patients require surgery usually within the first year of 
follow-up. 
         One of the  prophylactic measures attempted to prevent AUR in 
men with moderate to severe  LUTS and large sized prostate,  is the use 
of 5 alpha reductase inhibitors. Alpha blockers have also been used in 
symptomatic BPH patients to prevent AUR.  Its use can aid in voiding 
following catheter removal. Anticholinergic drugs   can be used in 
combination  with alpha blockers in patient with BPH. This combination 
does not increase the risk of AUR. The time to surgery after AUR can 
be delayed with the use of alpha blockers and in patients who is 
responding well, surgery can even be avoided. However conclusive 
evidence to prove  reduction  of risk of AUR with  the use of finasteride 
and  α-blockers is still lacking. 
           In the past, an episode of AUR was an absolute indication for 
surgery. Between twenty five to thirty percent  of men who underwent 
transurethral resection of the prostate (TURP) in the past had AUR as 
their main indication for surgery.5 At present only those patients who  
fails trial without catheter  undergo surgery.                         
           TURP is the treatment of choice if a patient fails trial without 
catheter. It is the  “gold standard”.  Other minimally invasive procedures 
can be considered in poor-risk patients. The safety and efficacy of these 
procedures, however, is yet to be determined. 
          In contrast to patients presenting with symptoms only ,TURP  has 
been found to be associated with  increased morbidity and mortality in 
men with AUR .  Delayed TURP is associated with lower morbidity and 
mortality than urgent intervention  in a patient who  had an episode of 
AUR. Hence , it is justifiable to attempt primary prevention of AUR 
especially in those patients with increased risk such as older patients, 
patients with severe symptoms, larger sized  glands, and increased PSA 
levels.  
          We planned to determine the factors that can predict which 
patients can  go in for urinary retention by comparing patients who had 
AUR  - with patients presented only with LUTS (non AUR). Those 
patients who are  at increased risk can be offered earlier treatment 
options, either medical management (α - blockers or 5 α reductase 
inhibitors) or surgery (TURP).   
          We compared the following factors between AUR  and non  AUR 
groups.    
1.Age, 2.comorbid illnesses, 3.previous history of urinary 
retention,4.IPSS symptom severity and grading ,5.prostate size grading 
as per digital rectal examination (DRE),Ultrasound evaluation- 6.size of 
prostate, 7.thickness of bladder wall, 8.intravesical protrusion grading, 
9. serum PSA level and 10.presence of urinary tract infection. 
       In our study among the 63 patients,2 patients in AUR group (one 
having  treatment with antidepressants,   one with neurogenic bladder 
dysfunction )and one in non AUR group ( biopsy confirmed Carcinoma 
prostate) were excluded. Both groups were analysed for statistical 
equality. 
 
 
1. AGE   
Age group: Both groups were matched for appropriate age. The 
mean age for  AUR group was 64.23 years and non AUR group  64.83. 
Age distribution: Most of the patients in both groups belong to 51 – 60 
years age group . there was no statistical significance between the 
various age groups between AUR and non AUR group as shown by p  
0.79.This is in correlation   with the observational study done by Kurita 
et al (1998)17 ,which showed no significant differences between the two 
groups in concern with age. In contradiction to the above results , 
various studies such as Olmsted county study ,(Jacebson et al -1997) 
6,the physician health study (Meigs et al -1999)13  and Berges  
et al(2000)16 –  all showed that advanced age was an important risk factor 
for AUR. 
2.COMORBID ILLNESSES  
There was no statistical significance in concern with presence of 
any of the comorbid illness like diabetes mellitus, systemic hypertension 
, ischemic heart disease, COPD, pulmonary tuberculosis between the 
AUR/non AUR groups. Eventhough Sasaki et al  (2003), 45 proposed 
presence of diabetes mellitus as one of the risk factor for AUR in BPH 
patients, our study was not correlating with that . 
3.PREVIOUS HISTORY OF  AUR: 
      There exists  a statistical significance  between AUR  and  non 
AUR groups with respect  to  past history of  urinary retention with  
a p 0.010. Our study was correlated with experience of  Breum et al 
(1982),2. As per this study ,in men with BPH, who had one episode of 
AUR - risk of second episode of  AUR was about  70-80% . 
 A study involving large database of 165,527 men with BPH , with 
AUR conducted by Cathcart et al.(2006)46.According to this study, 
increase in recurrent AUR was seen in patients who have not underwent 
surgical intervention following AUR. 
     Although the  likelihood of a second event of acute urinay 
retention after a Trial voiding without catheter (TWOC) was about 38-
56%. The risk of recurrent retention  depends on prostate size ,amount 
of post void residual urinary volume (PVR), and also the duration  
between catheterisation and the TWOC.47Klarskov et al.(1987) showed 
that after a single episode of acute urinary retention 85% of men 
required  surgical intervention within a follow up of one year,. 48A study 
involving 5,792 BPH men. who were offered conservative  management  
with drugs . This study done by Emberton M et al showed that prior 
episode of acute urinary retention was a strong predictor of recurrent 
episodes of acute urinary retention.49. All of the above were correlating 
well with our study.  
4. IPSS-SEVERITY AND GRADING  
       Most of the patients  in both groups presented with moderate IPSS 
score(8 -19) 
Mean IPSS score for AUR group was 20.6 and for non AUR 
group was 15.3 with a statistical significance , p   0.000.This is very 
well correlating with  various studies such as Olmsted county study, 
(Jacebson et al -1997) 6,the physician health study (Meigs et al -1999 )13, 
and  Berges et al(2000)16 all showed that IPSS symptom severity  is an 
important risk factor that predicts  AUR. 
Also  Marberger MJ et al ( 2000)19and the PLESS Study Group, 
Roehrborn CG et al ( 2000)21 , McConnell JD, (1998)14, Kaplan 
S(2000)20showed that IPSS symptom severity was an important 
predictor of AUR.   
However, observational study done by Kurita et al (1998)17, 
which showed no significant differences noted among the two groups in 
terms of  symptom severity, contradicting the above results. 
5.DIGITAL RECTAL EXAMINATION   - SIZE GRADING    
 DRE grading was done using length of vertical prominence  or 
encroachment in to the rectal lumen. Most of the patients in AUR group 
found to have GR II  (2 – 3 cm) enlargement , and in non AUR group 
had GR I enlargement (1- 2cm).There was no statistical significance 
observed among  the two groups in concern with size grading of the 
prostate by  DRE as shown by p  0.213. Since no universally accepted 
nomenclature describing prostatic size  by DRE is  available , and there 
are  no validated studies  available for comparing  the above result.   
6.  SIZE OF PROSTATE – USG STUDY 
Most of the patients in non AUR group found to have GR I  
enlargement( 21 – 40 gms) and in AUR group had GR II 
enlargement(41 -60 gms ). Mean volume of the prostate gland was about 
50.97gms in AUR group and in the non AUR group it was 35.43 with a 
statistical significance, p  0.003 this is very well correlating with   
Olmsted county study, (Jacebson et al -1997)6, showed that increase in 
size of the prostate is an important risk factor that predicts  AUR. 
      This was also confirmed by Marberger MJ et al ( 2000) 19 and the 
PLESS Study Group, Roehrborn CG et al ( 2000)21 , McConnell JD, 
(1998)14, Kaplan S(2000)20 showed that prostate volume  was an 
important predictor for AUR. 
Saboorian and colleagues ,conducted a study and  compared  the 
amount of tissue resected in men with  AUR and non AUR group.90 
men in AUR group and  87 men  of non AUR were compared . He 
observed a significant difference between the two groups .(30.1 ± 28.8 
SD vs 21.8 ± 25.6 SD cc; P < .01).18 
7. BLADDER WALL THICKNESS( BWT) - USG STUDY 
Most of the patients in AUR group had thickness of  more than 5 
mm, where as in the non AUR group it was less than 5mm with a 
statistical signifance , p  0.020.    
Mean bladder wall thickness in AUR group was 6.13 mm and in 
non AUR group it was 5.5mm with statistical significance , p- 0.024 
.This confirms the experience of   Manieriet al.(1996)50 who  reported  
BWT of> 5 mm was the good cut-off point to diagnose bladder outlet 
obstruction.88% of men with bladder wall thickness  >5 mm were found 
to be obstructed and only about  63% of men  with bladder wall 
thickness <5mm were found to have no obstruction. 
Kessler et al. (2006)51 showed that BWT ≥2.9 mm and Oelke et al. 
(2007) chose a cut-off of 2 mm  as a guide for diagnosing bladder  
outlet obstruction.52 
Contrary to above evidence, Abhishek Jain et al (2010) did not 
observe any statistically significant difference between patients with 
AUR and without AUR in terms of bladder wall thickness. This may be 
attributed due to difference heterogeneous patients group  and also 
variations in the patient duration of symptoms were not studied.53 
8. INTRA VESICAL PROTRUSION OF PROSTATE(IPP)-USG 
STUDY 
Most of the patients in AUR group had GR II IPP (5 – 10 mm) 
where as , in the non AUR group it was GR 0 (no IPP) with a statistical 
signifance , p  0.010. 
In the early 1990s, while doing transabdominal USG study for 
patients with lower urinary tract symptom (LUTS) suggestive of BPH 
for transurethral microwave thermal therapy, it was noticed that there 
was good correlation between the degree of protrusion of the prostate 
into the bladder cavity and the severity of obstruction as measured by a 
properly conducted uroflowmetry. Patients with minimal protrusion and 
a funneling bladder neck had good flow rates, whereas those with large 
intravesical protrusion had poor flow rates. 
      In a study conducted by Chia et al. (2003) 42 demonstrated that 
patients with grade 1 IPP were not obstructed, while 94% of grade 3 IPP 
were obstructed. The positive predictive value was 94%, while the 
negative predictive value was 79%.14 A similar study in Brazil showed 
that the receiveroperating characteristic (ROC) for IPP and bladder 
outlet obstruction (BOO) was 0.758 (95% confidence interval: 0.601-
0.876) and the cutoff point to indicate BOO was 5 mm with 95% 
sensitivity and 50% specificity.54 
In a study conducted by Tan and Foo et al(2003) - 55 of 100 
patients with acute urinary retention (AUR) who underwent trial off 
catheter, a grade 3 IPP was found to predict 67% failure rate. In contrast, 
64% of patients with grade 1 IPP were successful. With a follow-up of 6 
months, four patients who were initially trialed off successfully 
developed AUR again. Of these patients, three had grade 3 IPP, whereas 
one has grade 2, suggesting that a high-grade IPP was also predictive of 
recurrent AUR.56 
In a similar study, Zhang et al.(2006) with 115 patients  
on a trial off catheter in Jinan, China, showed concordant  
results with a failure rate of 31% for grade 1 IPP and 69% for grade 3 
IPP.57 
9.SERUM PSA  
      Most of the patients in non AUR group had PSA < 4 ng/ml   
whereas , in the  AUR group there were equal number of patients with  
< 4ng/ml and  4 – 10 ng /ml. Mean PSA level in the AUR group  
was about 6.01ng/ml and in the non AUR group it was 3.59ng /ml   
with a statistical signifance, p  0.026. 
      This was also confirmed by Marberger MJ et al ( 2000) 19 and the 
PLESS Study Group, Roehrborn CG et al ( 2000)21, McConnell JD, 
(1998)14, Kaplan S(2000)20  showed that increased serum PSA  
levels was an important predictor for AUR. 
Saboorian and colleagues (1993 )18 showed that  serum prostate-
specific antigen (PSA) done prior to surgery were also significantly 
different between AUR and non  AUR groups  (6.5 ± 5.5 SD vs 4.5 ± 
4.6 SD; P < .001),correlating well with our study. 
10.  URINE CULTURE AND SENSITIVITY  
 Most of the patients in both the groups showed no organisms 
grown  in urine culture. 
     Contrary to studies, John M Fitzpatrick et al (2012)59 
,Muruganandham et al (2007) 58, Herbert Lepor et al (2006)60  
considered ,urinary tract infection (UTI) as a risk factor for AUR, 
our study did not found any statistically significant difference  
between the AUR and non AUR groups in concern with urine  
culture positivity with a p  0.615.   
 
 
 
 
 
 
 
 
 
 
 
  
CONCLUSION 
      Symptom severity, previous AUR episodes, high serum PSA 
levels, increased size of prostate ,increased bladder wall thickness, 
increased intravesical prostatic projection are accurate predictors of 
acute urinary retention in patients with Benign Prostatic Hyperplasia. 
Those patients who are at risk can be offered earlier treatment options 
,could be either medical or surgical intervention to prevent AUR. 
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ABBREVIATIONS 
AUR – ACUTE URINARY RETENTION 
BPH- BENIGN PROSTATIC HYPERPLASIA  
BOO- BLADDER OUTLET OBSTRUCTION 
DRE- DIGITAL RECTAL EXAMINATION 
TURP- TRANS URETHRAL RESECTION OF PROSTATE  
LUTS- LOWER URINARY TRACT SYMPTOMS 
MTOPS- MEDICAL THERAPY OF PROSTATIC SYMPTOMS 
TRUS- TRANS RECTAL ULTRASOUND 
TWOC – TRIAL WITH OUT CATHETER  
BWT-  BLADDER WALL THICKNESS 
IPP – INTRAVESICAL PROSTATIC PROTRUSION 
ALFAUR- ALFUZOSIN IN ACUTE URINARY RETENTION  
IR – INTERMEDIATE RELEASING 
PVR –  POST VOID RESIDUAL URINE 
NSAIDS-  NON STEROIDAL ANTI INFLAMMATORY DRUGS 
PGE2- PROSTAGLANDIN  E -2 
UTI- URINARY TRACT INFECTION  
IPSS- INTERNATIONAL PROSTATE SYMPTOM SCORING 
PSA- PROSTATE SPECIFIC ANTIGEN  
PLESS- PROSCAR LONG TERM EFFICACY SAFETY AND 
STUDY 
SHT – SYSTEMIC HYPERTENSION  
DM – DIABETES MELLITUS 
IHD  -  ISCHEMIC  HEART DISEASE 
PT – PULMONARY TUBERCULOSIS 
COPD – CHRONIC  OBSTRUCTIVE PULMONARY DISEASE 
 
 
 
 
 
 
 
 
 
PROFORMA 
NAME: 
AGE: 
HOSPITAL NUMBER: 
DATE OF ADMISSION: 
PRESENT ILLNESS:  
 Incomplete emptying: 
 Frequency <2hours: 
 Weak stream: 
 Straining to void 
 Hesitancy  
 Intermittency  
 Urgency 
 Dysuria 
 Nocturia 
 Bowel habits, constipation: 
 Precipitating factor: anesthesia, non prostate related 
surgery, drugs. 
PAST HISTORY: 
 Previous history of AUR: 
 Type II diabetes mellitus, Parkinsons disease, stroke, 
spinal degenerative disease  and disc prolapse 
CLINICAL EXAMINATION: 
 General examination: 
 Abdominal examination : 
 Digital rectal examination: 
INVESTIGATIONS: 
 Urine routine- 
 Urine culture and sensitivity- 
 Renal parameters-  
 Sr. PSA- 
 USG abdomen and pelvis-  
-prostate volume    
-bladder  wall thickness (BWT) 
-presence of  intravesicalprostatic projection (IPP) 
-amount of post void residual urine (PVR)volume     
 Uroflowmetry- 
 Cystoscopy - 
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1 CHINNASWAMY 67 2 GRH 986034 0 0 0 0 0 0 11 2 1 34 1 5 0 0 1.8 0 0 NIL NO 
2 JOSEPH 75 3 GRH 986558 1 1 0 0 1 0 15 2 2 40 1 5 0 0 4.1 1 0 NIL NO 
3 KANNAN 65 2 GRH 987251 0 1 0 0 2 0 12 2 2 42 2 6 1 1 1.9 0 1 E.COLI NO 
4 SUBRAMNI 50 0 GRH 987719 0 0 0 0 0 0 15 2 1 22 1 5 0 0 0.9 0 2 PSEUDOMONAS NO 
5 VEERASAMY 60 1 GRH 988107 0 0 0 0 0 0 16 2 3 44 2 8 1 2 6.2 1 0 NIL NO 
6 SALIYA 74 3 GRH 988927 1 0 0 0 3 0 16 2 2 43 2 7 1 1 2.1 0 0 NIL NO 
7 PERIYASAMY 61 2 GRH 988927 0 1 0 0 2 0 13 2 1 44 2 6 1 2 5.2 1 1 E.COLI NO 
8 MURUGESAN 75 3 GRH 989831 1 0 0 0 3 0 19 2 2 48 2 5 0 1 2 0 0 NIL NO 
9 POONGAVANAM 60 1 GRH 989510 0 0 0 0 0 0 14 2 3 42 2 7 1 2 4.2 1 0 NIL NO 
10 RAJENDRAN 57 1 GRH 989810 1 0 1 0 4 0 21 3 1 30 1 5 0 0 1.4 0 0 NIL NO 
11 VEDAGIRI 70 2 GRH 990001 0 1 1 0 5 0 10 2 1 36 1 6 1 0 6.8 1 0 NIL NO 
12 FELIX 
BENEDICT 
59 1 GRH 998108 0 0 0 0 0 0 15 2 1 32 1 5 0 0 3.2 0 2 PSUEDOMONAS NO 
13 MURUGAN 53 1 GRH 990113 0 0 0 0 0 0 16 2 2 54 2 5 0 1 4.8 1 0 NIL NO 
14 ELLAPPAN 75 3 GRH 997125 0 0 0 1 7 0 17 2 1 28 1 4 0 0 1.9 0 0 NIL NO 
15 ARUMUGAM 76 3 GRH 998456 1 1 0 0 1 0 16 2 2 38 1 4 0 0 6 1 0 NIL NO 
16 NAVANEETHAM 65 2 GKMCH 8020 0 0 0 0 0 0 14 2 1 30 1 5 0 0 3.9 0 3 STAPH AUREUS NO 
17 MANI 60 1 GKMCH 9938 0 0 0 0 0 0 14 2 1 22 1 5 0 0 2.3 0 0 NIL NO 
18 KANNAN 56 1 GKMCH 25534 0 1 0 0 2 0 12 2 0 27 1 6 1 0 3 0 1 E.COLI NO 
19 MURUGAN 56 1 GKMCH 25750 1 0 0 0 3 0 16 2 1 40 1 5 0 1 2.8 0 0 NIL NO 
20 BALAKRISHNAN 78 3 GKMCH 27006 0 0 0 0 0 1 14 2 1 38 1 5 0 0 3.9 0 2 PSUEDOMONAS NO 
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21 THANGASAMY 70 2 GRH 110082 1 1 1 0 6 0 22 3 1 22 1 6 1 0 1.6 0 0 NIL NO 
22 PERUMAL 70 2 GRH 110911 0 0 0 0 0 0 16 2 0 28 1 5 0 0 1.8 0 0 NIL NO 
23 RAMAIAH 76 3 GRH 112584 0 0 0 0 0 0 14 2 2 100 4 7 1 3 5.2 1 1 E.COLI NO 
24 KALIAPERUMAL 75 3 GRH 112592 1 0 0 0 3 0 14 2 2 32 1 5 0 0 1.8 0 0 NIL NO 
25 KANNAN 56 1 GRH 111989 0 0 0 0 0 0 16 2 2 46 2 5 0 1 3.8 0 0 NIL NO 
26 KARUPIAH 59 1 GRH 112586 0 0 0 0 0 1 14 2 2 61 3 5 0 2 5.2 1 1 E.COLI NO 
27 MURUGAPILLAI 54 1 GRH 114063 0 0 0 0 0 0 13 2 2 65 3 8 1 2 1.8 0 4 KLEBSIELA NO 
28 RAMASWAMY 58 1 GRH 114528 0 1 0 0 2 0 24 3 1 42 2 5 0 0 5.1 1 4 KLEBSIELA NO 
29 RADHAKRISHNAN 60 1 GRH 114289 0 1 0 0 2 0 17 2 2 42 2 6 1 1 8.2 1 0 NIL NO 
30 MUTHUSWAMY 75 3 GRH 114527 0 1 0 0 2 0 13 2 1 37 1 4 0 0 4.9 1 4 KLEBSIELLA NO 
31 KASIM SAHIB 51 1 GRH 985787 0 0 0 0 0 1 12 2 1 28 1 8 1 1 1.2 0 1 E.COLI YES 
32 DHANABAL 75 3 GRH 986023 0 0 0 0 0 0 17 2 1 42 2 5 0 2 8.1 1 0 NIL YES 
33 ABIBULLAH 55 1 GRH 986028 1 1 0 0 1 0 30 3 2 27 1 7 1 1 4.2 1 0 NIL YES 
34 RANGASAMY 62 2 GRH 986022 1 0 0 0 3 1 18 2 2 51 2 5 0 2 1.8 0 0 NIL YES 
35 MEERAIYA 79 3 GRH 988166 0 1 0 0 2 1 17 2 2 40 1 6 1 1 9.8 1 4 KLEBSIELA YES 
36 VEERANAN 60 1 GRH 987630 1 0 0 0 3 1 19 2 2 48 2 5 0 2 3.4 0 1 E.COLI YES 
37 PERUMAL 67 2 GRH 989632 1 1 0 0 1 0 29 3 3 61 3 8 1 3 6 1 4 KLEBSIELA YES 
38 MEERAN 60 1 GRH 989625 0 0 0 0 0 0 31 3 3 51 2 6 1 2 5.1 1 0 NIL YES 
39 GOVINDASAMY 60 1 GRH 989821 1 1 1 0 6 0 17 2 2 42 2 7 1 1 9.8 1 0 NIL YES 
40 SUNDARAVADIVELAN 60 1 GRH 990429 0 0 0 0 0 0 17 2 1 44 2 6 1 0 5.8 1 0 NIL YES 
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41 ANNAMALAI 58 1 GRH 991293 0 1 1 0 5 0 29 3 3 61 3 6 1 2 1.2 0 1 E.COLI YES 
42 RAGU 62 2 GRH 997995 0 0 0 0 0 1 28 3 2 54 2 6 1 1 5.1 1 4 KLEBSIELLA YES 
43 BALAN 72 3 GRH 998212 1 1 0 0 1 0 16 2 2 46 2 6 1 1 4.1 1 0 NIL YES 
44 KUPPUSWAMY 50 0 GRH 100686 0 0 0 0 0 0 18 2 1 38 1 5 0 0 3.1 0 0 NIL YES 
45 KAMALUDEEN 62 2 GRH 101656 1 0 0 0 3 1 19 2 2 54 2 6 1 2 8.2 1 1 E.COLI YES 
46 KULASEKARAN 57 1 GKMCH 7868 0 0 0 0 0 0 20 3 1 20 0 7 1 0 1.9 0 2 PSUEDOMONAS YES 
47 MANICKAM 83 4 GKMCH 6323 0 0 0 0 0 0 25 3 1 46 2 7 1 1 14 2 0 NIL YES 
48 ARUMUGAM 52 1 GKMCH 25071 0 0 0 0 0 0 34 3 2 29 1 7 1 1 2.3 0 0 NIL YES 
49 SRINIVASAN 83 4 GKMCH 25522 1 0 0 0 3 1 16 2 2 59 2 4 0 2 4.2 1 0 NIL YES 
50 MUNUSWAMY 56 1 GKMCH 24825 0 0 0 0 0 0 16 2 2 54 2 7 1 2 4.2 1 4 KLEBSIELLA YES 
51 GOVINDASAMY 65 2 GKMCH 26983 1 0 0 0 3 1 18 2 2 56 2 5 0 2 3.1 0 4 KLEBSIELLA YES 
52 ABDUL REHMAN 68 2 GKMCH 25519 1 1 0 0 1 0 17 2 2 67 3 5 0 3 10.1 2 1 E.COLI YES 
53 GOPAL 58 1 GKMCH 31039 0 1 1 0 5 0 18 2 2 35 1 5 0 0 2.9 0 0 NIL YES 
54 BALU 59 1 GKMCH 28729 0 0 0 1 7 0 19 2 1 36 1 7 1 0 4 0 0 NIL YES 
55 KASINATHAN 62 2 GKMCH 29621 0 1 0 0 2 0 17 2 1 120 4 5 0 3 28 2 0 NIL YES 
56 ESURAJAN 65 2 GRH 110541 0 0 0 0 0 1 29 3 2 60 2 7 1 1 3.1 0 1 E.COLI YES 
57 SELVARAJ 76 3 GRH 110668 1 1 0 0 1 1 16 2 1 24 1 5 0 1 2.4 0 2 PSUEDOMONAS YES 
58 SUNDRAMOORTHY 71 3 GRH 110083 1 1 0 0 1 0 19 2 2 101 4 8 1 3 3.3 0 1 E.COLI YES 
59 KRISHNAN 70 2 GRH 113312 0 0 0 0 0 0 18 2 2 61 3 6 1 2 4.2 1 0 NIL YES 
60 FRANCIS 69 2 GRH 114580 1 0 0 0 3 0 19 2 2 95 4 7 1 2 16 2 1 E.COLI YES 
